| First Author | Yoshioka T | Year | 2019 |
| Journal | Am J Pathol | Volume | 189 |
| Issue | 7 | Pages | 1338-1350 |
| PubMed ID | 31014956 | Mgi Jnum | J:287640 |
| Mgi Id | MGI:6416713 | Doi | 10.1016/j.ajpath.2019.04.003 |
| Citation | Yoshioka T, et al. (2019) CD147/Basigin Deficiency Prevents the Development of Podocyte Injury through FAK Signaling. Am J Pathol 189(7):1338-1350 |
| abstractText | Podocytes, which are susceptible to injury by various stimuli and stress, are critical regulators of proteinuric kidney diseases, regardless of the primary disease and pathogenesis. We further confirmed a significant correlation between urinary CD147/basigin (Bsg) levels and proteinuria in patients with focal segmental glomerulosclerosis. However, the molecular mechanism of podocyte injury involving Bsg is not fully understood. Here, the involvement of Bsg in the pathogenesis of podocyte injury was elucidated. Healthy podocytes rarely express Bsg protein. In two independent mouse models, including adriamycin-induced nephropathy and N(omega)-nitro-l-arginine methyl ester (l-name)-induced endothelial dysfunction, Bsg induction in injured podocytes caused podocyte effacement, which led to development of proteinuria. Bsg silencing in cultured podocytes exposed to transforming growth factor-beta suppressed focal adhesion rearrangement and cellular motility via the activation of beta1 integrin-focal adhesion kinase-matrix metallopeptidase signaling. In addition, induction of vascular endothelial growth factor and endothelin-1, which are implicated in podocyte-to-endothelial cross-communication, was lower in the supernatants of cultured Bsg-silenced podocytes stimulated with transforming growth factor-beta. In this setting, Bsg may be involved in a physiological positive feedback loop that accelerates podocyte cell motility and depolarization. The current study thus suggests that Bsg silencing via suppression of beta1 integrin-focal adhesion kinase-matrix metallopeptidase signaling may be an attractive therapeutic strategy for the maintenance of podocytes in patients with proteinuric kidney diseases. |
